Celgene Stock Soars on Promising Pancreatic Cancer Drug Data

Celgene, which unexpectedly reported the results late on Friday, did not give details of the extent of the improvement, saying it would do so at a medical meeting in January.

Abraxane is already approved to treat breast and lung cancer and the company will apply for approval from regulators to market the drug to treat pancreatic cancer as well.

Read the full story: http://reut.rs/SSY3jl

Source: Reuters